INDV Q1 2025 Earnings — Indivior Pharmaceuticals Inc Revenue & Financial Results | Market Cap Arena

INDVIndivior Pharmaceuticals Inc

$4B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$266M-6.3% YoY

Gross Profit

$222M83.5% margin

Operating Income

$66M24.8% margin

Net Income

$47M17.7% margin

EPS (Diluted)

$0.38

QoQ Revenue Growth

-11.0%

Cash Flow

Operating Cash Flow

$75M

Free Cash Flow

$70M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$1.4B

Total Liabilities

$1.7B

Stockholders' Equity

-$286M

Cash & Equivalents

$372M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$266M	$284M	-6.3%
Gross Profit	$222M	$246M	-9.8%
Operating Income	$66M	$75M	-12.0%
Net Income	$47M	$61M	-23.0%

Revenue Segments

Reportable Segment

$266M100%